The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro

Anticancer Research

Volumn 30, Issue 1, 2010, Pages 149-156

  Larsson, Dhana E ^a   Wickström, Malin ^a   Hassan, Sadia ^a   Öberg, Kjell ^a   Granberg, Dan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Brefeldin A; Caspase activity; NSC 95397

Indexed keywords

BORTEZOMIB; BREFELDIN A; CASPASE 3; CYTOTOXIC AGENT; NSC 95397; SANGUINARINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL MEMBRANE; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TUMOR CELL LINE;

APOPTOSIS; BENZOPHENANTHRIDINES; BORONIC ACIDS; BREFELDIN A; CARCINOID TUMOR; CARCINOMA, BRONCHOGENIC; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISOQUINOLINES; LUNG NEOPLASMS; NAPHTHOQUINONES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRAZINES;

EID: 77649257413     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
2. Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2000.
3. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
4. Cryns V and Yuan Y: Protease to die for. Genes Dev 12: 1551-1570, 1998.
5. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotheraphy. Oncogene 25: 4798-4811, 2006.
6. Li P, Nijhawan D, Budihardjo I, Srinivasula, SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
7. Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161: 2833-2840, 1998.
8. Ravichandran KS: "Recruitment signals" from apoptotic cells: invitation to a quiet meal Cell 113: 817-820, 2003.
9. Makin G and Hickmann JA: Apoptosis and cancer chemotherapy. Cell Tissue Res 301: 143-152, 2000.
10. Bedner E, Smolewski P, Amstad P and Darzynkiewicz Z: Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation. Exp Cell Res 259: 308-313, 2000.
11. Giuliano KA, DeBasio RL, Dunlay RT, Dunlay T, Gough A, Volosky JM, Zock J, Pavlakis GN and Taylor DL: High-content screening: a new approach to easing key bottlenecks in the drug discovery process. J Biomol Screen 2: 249-259, 1997.
12. Lovborg H, Nygren P and Larsson R: Multiparametric evaluation of apoptosis effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther 3: 521-526, 2004.
13. Larsson DE, Lovborg H, Rickardson L, Larsson R, Oberg K and Granberg D: Identification and evaluation of potential anticancer drugs on human neuroendocrine tumor cell lines. Anticancer Res 26: 4125-4129, 2006.
14. Larsson DE, Hassan S, Larsson R, Oberg K and Granberg D: Combination analyses of anti-cancer drugs on humanneuro-endocrine tumor cell lines. Cancer Chemother Pharmacol 65: 5-12, 2009.
15. Vogt A, Kalb EN and Lazo JS: A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity. Oncology Res 14: 305-314, 2004.
16. Beauparlant P and Shore GC: Therapeutic activation of caspases in cancer: a question of selectivity. Curr Opin Drug Discov Dev 6: 179-187, 2003.
17. Gasparri F, Mariani M, Sola F and Galvani A: Quantification of the proliferation index of human dermal fibroblast cultures with the ArrayScan highcontent screening reader. J Biomol Screen 9: 232-243, 2004.
18. Wilson CJ, Si Y, Thompsons CM, Smellie A, Ashwell MA, Liu JF, Ye P, Yohannes D and Ng SC: Identification of a small molecule that induces mitotic arrest using a simplified high-content screening assay and data analysis method. J Biomol Screen 11: 21-28, 2006.
19. Ramm P, Alexandrov Y, Cholewinski A, Cybuch Y, Nadon R and Soltys BJ: Automated screening of neurite outgrowth. J Biomol Screen 8: 7-18, 2003.
20. Bertelsen M and Sanfridson A: Inflammatory pathway analysis using a high content screening platform. Assay Drug Dev Technol 3: 261-271, 2005.
21. Lazo JS, Nemoto K, Pestell KE, Cooley K, Southwick EC, Mitchell DA, Furey W, Gussio R, Zaharevitz DW, Joo B and Wipf P: Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol 61: 720-728, 2002.
22. Kristjansdottir K and Rudolph J: Cdc25 phosphatases and cancer. Chem Biol 11: 1043-1051, 2004.
23. Ludwig H, Khayat D, Giaccone G and Facon T: Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104: 1794-1807, 2005.
24. Myung J, Kim KB and Crews CM: The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21: 245-273, 2001.
25. Adams J, Palombella VJ and Elliott PJ: Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18: 109-121, 2000.
26. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
27. Adhami VM, Aziz MH, Reagan-Shaw SR, Nihal M, Mukhtar H and Ahmad N: Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin- dependent kinase machinery. Mol Cancer Ther 3: 933-940, 2004.
28. Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH and Higano CS: Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clinical Cancer Res 10: 1306-13011, 2004.
29. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P and Grant S: The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 63: 1822-1833, 2003.
30. Kim S, Lee TJ, Leem J, Choi KS, Park JW and Kwon TK: Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL. J Cell Biochem 104: 895-907, 2008.
31. Hussain AR, Al-Jomah NA, Siraj AK, Manogaran K, Al-Hussein K, Abubaker J, Platanias LC, Al-Kuraya KS and Uddin S: Sanguinarine dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 67: 3888-3897, 2007.
32. Jang BC, Park JG, Song DK, Baek WK, Yoo SK, Jung KH, Park GY, Lee TY and Suh SI: Sanguinarine induces apoptosis in A549 human lung cancer cells primarily via cellular glutathione depletion. Toxicol In Vitro 23: 281-287, 2009.
33. Salles FT, Hespanhol AM, Jaeger RG and Marques MM: Brefeldin-A induces apoptosis in human adenoid cystic carcinoma cultured cells. Oral Oncol 40: 585-590, 2004.